Reported 0 shares, down 1,090,087 (100.0%) from the prior quarter.
Reported value -100.0%; share count -100.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-09-30 | 2235000 |
| 2021-12-31 | 2047000 |
| 2022-03-31 | 2275000 |
| 2022-06-30 | 410000 |
| 2022-09-30 | 492000 |
| 2022-12-31 | 879550 |
| 2023-03-31 | 1826639 |
| 2023-06-30 | 10680620 |
| 2023-09-30 | 15022004 |
| 2023-12-31 | 25747855 |
| 2024-03-31 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q1 2024 | Reduced | 0 | -1,090,087 (-100.0%) | 0 | $0 | 2024-05-14 | |
| Q4 2023 | Added | 1,090,087 | +82,575 (8.2%) | < 0.01% | $25,747,855 | 2024-02-13 | |
| Q3 2023 | Added | 1,007,512 | +32,113 (3.3%) | < 0.01% | $15,022,004 | 2023-11-13 | |
| Q2 2023 | Added | 975,399 | +765,922 (365.6%) | < 0.01% | $10,680,620 | 2023-08-11 | |
| Q1 2023 | Added | 209,477 | +69,198 (49.3%) | < 0.01% | $1,826,639 | 2023-05-15 | |
| Q4 2022 | Reduced | 140,279 | -230 (-0.2%) | < 0.01% | $879,550 | 2023-02-13 | |
| Q3 2022 | Added | 140,509 | +1,520 (1.1%) | < 0.01% | $492,000 | 2022-11-14 | |
| Q2 2022 | Reduced | 138,989 | -592,728 (-81.0%) | < 0.01% | $410,000 | 2022-08-12 | |
| Q1 2022 | Added | 731,717 | +125,989 (20.8%) | < 0.01% | $2,275,000 | 2022-05-13 | |
| Q4 2021 | Reduced | 605,728 | -6,754 (-1.1%) | < 0.01% | $2,047,000 | 2022-02-08 | |
| Q3 2021 | Reduced | 612,482 | -25,744 (-4.0%) | < 0.01% | $2,235,000 | 2021-11-15 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
200 managers reported CYMABAY THERAPEUTICS INC for Q1 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| IFP Advisors Inc | Unchanged | 650 | 0 | < 0.01% | $21,077 | 19 qtrs |
| Legato Capital Management LLC | Reduced | 0 | -40,393 | 0 | $0 | 3 qtrs |
| VANGUARD GROUP INC | Reduced | 0 | -6,306,149 | 0 | $0 | 39 qtrs |
| Novo Holdings A S | Reduced | 0 | -900,000 | 0 | $0 | 4 qtrs |
| J Goldman & Co LP | Reduced | 0 | -165,937 | 0 | $0 | 3 qtrs |
| ALGERT GLOBAL LLC | Reduced | 0 | -84,883 | 0 | $0 | 16 qtrs |
| Entropy Technologies LP | Reduced | 0 | -27,116 | 0 | $0 | 2 qtrs |
| JANUS HENDERSON GROUP PLC | Reduced | 0 | -6,103,797 | 0 | $0 | 6 qtrs |
| BIT Capital GmbH | Reduced | 0 | -8,206 | 0 | $0 | 3 qtrs |
| Truvestments Capital LLC | Reduced | 0 | -1,364 | 0 | $0 | 13 qtrs |
Filing details and methodology As reported
- Report period
- March 31, 2024
- Filed
- May 14, 2024
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.